SBK & ASA biomechanically safer than LASIK

Article

With regards to maintaining corneal biomechanics, sub-Bowman's keratomileusis (SBK) and advanced surface ablation (ASA) are improvements over conventional LASIK.

With regards to maintaining corneal biomechanics, sub-Bowman's keratomileusis (SBK) and advanced surface ablation (ASA) are improvements over conventional LASIK, according to a report published in the January issue of the Journal of Refractive Surgery.

Daniel Dawson and colleagues from Emory University and Emory Vision, Atlanta, Georgia, USA conducted histologic, ultrastructual and cohesive tensile strength evaluations on 25 normal human corneal specimens, 206 uncomplicated LASIK specimens, 17 uncomplicated SBK specimens, four uncomplicated PRK specimens, two uncomplicated ASA specimens, five keratoconus specimens, 12 postoperative LASIK ectasia specimens and one postoperative PRK ectasia specimen compared with previously published studies.

The researchers found that histological and ultrastructual studies of normal corneas revealed significant differences in the direction of collagen fibrils and/or the degree of lamellar interweaving in Bowman's layer, the anterior third of the corneal stroma, the posterior two-thirds of the corneal stroma and Descemet's membrane. Cohesive tensile strength testing supported these findings, as the stronger, more rigid regions of the cornea were located anteriorly and peripherally.

These results suggest that ASA, and secondarily SBK, should be biomechanically safer than conventional LASIK with regard the risk of causing keratectasia.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.